Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Recurrent Glioblastoma
NCT02981940Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2017
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in glioblastoma (GBM) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Intratumoral Abemaciclib Concentration and 6-Month Progression Free Survival. Started Feb 2017; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02981940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981940.